Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure

We present a case report of a neonate receiving raltegravir-based postnatal HIV prophylaxis after in utero dolutegravir exposure. High levels of raltegravir and dolutegravir can potentially cause bilirubin toxicity as they compete for albumin binding and follow the same metabolic pathway through UGT...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobs, Tom G., van Aerde, Koen J., Colbers, Angela, Burger, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
HIV Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740601/
https://www.ncbi.nlm.nih.gov/pubmed/35017453
http://dx.doi.org/10.1097/INF.0000000000003364
_version_ 1784629343031394304
author Jacobs, Tom G.
van Aerde, Koen J.
Colbers, Angela
Burger, David M.
author_facet Jacobs, Tom G.
van Aerde, Koen J.
Colbers, Angela
Burger, David M.
author_sort Jacobs, Tom G.
collection PubMed
description We present a case report of a neonate receiving raltegravir-based postnatal HIV prophylaxis after in utero dolutegravir exposure. High levels of raltegravir and dolutegravir can potentially cause bilirubin toxicity as they compete for albumin binding and follow the same metabolic pathway through UGT1A1. This case suggests delaying initiation of raltegravir-based postnatal prophylaxis by 24–48 hours after in utero dolutegravir exposure.
format Online
Article
Text
id pubmed-8740601
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-87406012022-01-14 Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure Jacobs, Tom G. van Aerde, Koen J. Colbers, Angela Burger, David M. Pediatr Infect Dis J HIV Reports We present a case report of a neonate receiving raltegravir-based postnatal HIV prophylaxis after in utero dolutegravir exposure. High levels of raltegravir and dolutegravir can potentially cause bilirubin toxicity as they compete for albumin binding and follow the same metabolic pathway through UGT1A1. This case suggests delaying initiation of raltegravir-based postnatal prophylaxis by 24–48 hours after in utero dolutegravir exposure. Lippincott Williams & Wilkins 2022-01-10 2022-02 /pmc/articles/PMC8740601/ /pubmed/35017453 http://dx.doi.org/10.1097/INF.0000000000003364 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle HIV Reports
Jacobs, Tom G.
van Aerde, Koen J.
Colbers, Angela
Burger, David M.
Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure
title Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure
title_full Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure
title_fullStr Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure
title_full_unstemmed Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure
title_short Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure
title_sort raltegravir-based postnatal hiv prophylaxis therapy in a neonate after in utero dolutegravir exposure
topic HIV Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740601/
https://www.ncbi.nlm.nih.gov/pubmed/35017453
http://dx.doi.org/10.1097/INF.0000000000003364
work_keys_str_mv AT jacobstomg raltegravirbasedpostnatalhivprophylaxistherapyinaneonateafterinuterodolutegravirexposure
AT vanaerdekoenj raltegravirbasedpostnatalhivprophylaxistherapyinaneonateafterinuterodolutegravirexposure
AT colbersangela raltegravirbasedpostnatalhivprophylaxistherapyinaneonateafterinuterodolutegravirexposure
AT burgerdavidm raltegravirbasedpostnatalhivprophylaxistherapyinaneonateafterinuterodolutegravirexposure

Ejemplares similares